Nothing new on Personalisin the last three months. We read the news on it every day, write up anything that matters once a week, and tell you sooner if something can't wait. A quiet stretch is normal and is not a signal by itself.
Personalis analyst price targets
Average target$16.44+11%vs $14.80 today
TodayAvg price
Low $16.25High $17
Buy12 analysts
0Bearish
4Neutral
8Bullish
FirmRatingPrice TargetDate
Craig-Hallum
Hold
$16.25
8/24/2026
BTIG
Neutral
$11→$16.25
7/21/2026
Lake Street
Hold
$16.25
7/20/2026
Needham
Hold
$17
7/17/2026
Morgan Stanley
Equal Weight
$10→$9
5/12/2026
BTIG
Neutral
$13→$11
5/11/2026
Guggenheim
Buy
$12→$13
1/26/2026
Morgan Stanley
Equal Weight
$11
12/1/2025
Personalis earnings
The company has a history of beating revenue targets even while losing money, showing that its cancer tests are finding a market faster than expected.
Earnings history
EstimateBeatMiss
Personalis past earnings results
Expected
Actual
Surprise
EPS
$-0.26
$-0.30
-13.9%
Revenue
$17M
$22M
+34.0%
Key highlights
Clinical revenue surge: Clinical diagnostic revenue grew 442% to $2.6 million as the company secured more Medicare coverage for its cancer recurrence tests. These tests are the main focus of the company's growth strategy, and they now make up a larger slice of the business than the $0.5 million they contributed a year ago.
Clinical test volume momentum: The number of clinical tests delivered jumped 199% to 10,384 compared to 3,478 tests in the same quarter last year. This growth is being driven by a wider group of doctors, with over 1,400 physicians now ordering the company's NeXT Personal test.
Operating loss widens: The loss from operations, which is the money the company loses running its daily business, increased to $33.6 million compared to a loss of $21.8 million a year ago. Expenses rose across the board, with selling and administrative costs jumping to $22 million as the company expanded its marketing and sales reach.
Tempus merger pending: The company entered into an agreement to be acquired by Tempus AI on July 20, 2026. Because of this pending merger, the company has stopped giving detailed financial guidance or holding earnings calls to answer questions.
Clinical revenue outlook: Management expects clinical revenue to grow by more than 500% for the full year compared to 2025. This target relies on the company successfully getting insurance to pay for more types of cancer monitoring throughout the rest of the year.
Our take: This was a strong operational quarter for the core clinical business, though the bottom line suffered as the company spent heavily to grow. The 199% jump in test volume shows real demand, and the pending acquisition by Tempus AI likely provides the necessary scale to keep this momentum going. It solidifies the growth path even while quarterly losses remain high.
Personalis’s next earnings date
Q3 2026
NOV
3
Expectation
EPS
$-0.26
Revenue
$22M
Metrics we are tracking
Metric
Expectations
Status
Clinical Test Volume
Growing above 100% year over year for two consecutive quarters
10,384 tests in Q2 2026
Clinical Revenue Growth
Sustaining above 300% YoY growth as Medicare coverage scales
442% YoY in Q2 2026
Gross Margin
Improving toward 30% as laboratory volumes increase
13% in Q2 2026
Physicians Ordering
Reaching over 2,000 active ordering physicians
1,400 as of Q2 2026
Stay on top of Personalis
Follow Personalis to get the latest and most important updates.